Completed OBSERVATIONAL NCT01071681

Survey to Assess Why People Are Not Responding to Treatment in Hypertension

Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.

Sponsor: Bayer

Conditions Arterial Hypertension

Interventions Telmisartan (Kinzal/Pritor, BAY68-9291)

Updated 9 times since 2017 Last updated: Nov 1, 2011 Started: Nov 30, 2009 Primary completion: Sep 30, 2010 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Arterial Hypertension and is currently completed. Bayer leads this study, which shows 9 recorded versions since 2009 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Feb 2020 — Jan 2021 [monthly]

Completed
Jun 2018 — Feb 2020 [monthly]

Completed

▶ Show 4 earlier versions

May 2018 — Jun 2018 [monthly]

Completed
Apr 2018 — May 2018 [monthly]

Completed

Phase: NA → None
Aug 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Aug 2017 [monthly]

Completed NA

First recorded

Nov 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bayer
International Clinical Trials Association

Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Many Locations, France